CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 4 enrolled
Drug / intervention
Ropivacainedrug
Likely dose
Ropivacaine 0.3mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04298099
NCT04298099Phase 4Completed
CompareCT.gov

Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population

Baylor College of Medicine·interventional·Posted Mar 6, 2020·Updated May 17, 2024

In Brief

A Phase 4 clinical trial evaluating Ropivacaine for Anesthesia, Local. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The primary aim of this study is to evaluate the pharmacokinetics of serum ropivacaine concentrations following erector spinae plane peripheral nerve blocks in the pediatric population. Secondary outcomes will assess the efficacy of the block with perioperative morphine equivalent consumption and pain scores.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Local
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMar 6, 2020
Enrollment StartDec 18, 2020
Primary CompletionJan 27, 2021
Study CompletionMar 29, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.3 years ago

Interventions

Ropivacainedrug

Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.